

## OIFE Webinar: Update on clinical trials in osteogenesis imperfecta 24 October 2023, 19:30-21:00 CET

A webinar with the goal of updating the OI-community about ongoing clinical trials in osteogenesis imperfecta, in adults and in children, including trials which are recruiting and others. Target group is anyone interested. Register here: <https://forms.gle/krsjjo8RnvV2b6sj8>

### Programme

19:30	Welcome and introduction
19:35	Update on Orbit: Clinical Study to assess efficacy and safety of Setrusumab in individuals with Osteogenesis Imperfecta ages 5 – 26 <i>Stan Krolczyk, Vice President Global Medical Affairs Strategy and Evidence Generation, Ultragenyx</i>
19:50	Update on Cosmic: Clinical Study to evaluate the effect of Setrusumab versus IV – Bisphosphonate in children with Osteogenesis Imperfecta <i>Stan Krolczyk, Vice President Global Medical Affairs Strategy and Evidence Generation, Ultragenyx</i>
20:05	Project SATURN - a Real-World Evidence & Data Collaboration with Existing European Datasets in Osteogenesis Imperfecta to Support Future Therapies <i>James Clancy, Senior Director, Clinical Operations, Mereo BioPharma</i>
20:15	POISE-1: TGF- $\beta$ Antibody for the Treatment of Osteogenesis Imperfecta <i>Cemre Robinson, Clinical Research Director, Rare Bone Disease R&amp;D, Sanofi</i>
20:30	TOPaZ, Treatment of Osteogenesis Imperfecta with Teriparatide and Zoledronic Acid Trial <i>Stuart Ralston, Professor of Rheumatology, University of Edinburgh, and Chief Investigator, TOPAZ Trial</i>
20:45	The BOOSTB <sub>4</sub> Clinical Trial <i>Carlos Camozzi, MD, Medical Advisor, BOOST Pharma</i>
20:55	Summing up
21:00	End



Read more about [ongoing clinical trials at OIFE's webpage](#).